Plasmodium falciparum in Cambodia

From MicrobeWiki, the student-edited microbiology resource
Revision as of 20:27, 14 May 2010 by BarichD (talk | contribs)
Jump to: navigation, search
This map shows the locations where mefloquine-resistant malaria is found in Cambodia and surrounding countries. (12)


Malaria: The Disease

Malaria is fatal disease that has infected about 515 million people worldwide and kills nearly a million people annually (1). It is widespread mostly in tropical and subtropical countries where conditions allow the Anopheles mosquitoes to thrive.

Very often malaria is found in economically poor countries, where people are unable to afford preventive vaccinations or any medical treatments. Throughout the years it has been shown that poverty and malaria are inter-linked, one affects the other. People in poverty, individual or family, may not be able to pay for their transportation, consultation with doctors and, of course, for their treatment (such as anti-malarial drugs) fees at health facilities (21).

There are four types of human malaria: Plasmodium(P) falciparum, Plasmodium vivax, Plasmodium malariae and Plasmodium oval. Among these four, P. falciparum and P. vivax are the most common ones, with P. falciparum causing the most number of deaths.

A diagram of the basic symptoms of malaria. (30)

Malaria is a disease that includes symptoms such as fever, abdominal pain, chills, headaches, nausea, diarrhea and vomiting, which can appear after couple of days or weeks after the infection. Also, very often malaria can lead to severe anemia, seizures, kidney failure, confusion and death if not treated on time (5).

An interesting study shows that in Southeast Asia malaria was first transmitted to humans by chimpanzees and not by mosquitoes (20). The parasite Plasmodium knowlesi is found in monkeys only. There have also been found some similarities between the human and monkey parasites which suggested that those two strains might have evolved from a common ancestor millions of years ago. As a result of these findings, researchers are now wondering if P. knowlesi is the fifth human malaria.

As a result of its devastating effects on the human population, many organizations, such as the Gates Foundation, and countries have banded together to find preventative measures and treatments for this global epidemic.

Description of Malaria

In Cambodia, the specific species Anopheles dirus, A. minimus, and A. sundaicus transmit the malaria-causing parasites (Plasmodium falciparum and P. vivax) to the host during feeding with the bite, transmitting the parasite through their saliva (2).

The parasite initially enters the liver, where it multiplies and then infects the red blood cells. Here, parasites still continue to multiply until eventually the red blood cells burst and the parasite appears in the plasma. Now, the parasites are free in the plasma and will infect any mosquito that bites and feeds on the host’s blood. Once the parasites enter the mosquito, they are also found in its saliva and are ready to be transferred to another individual and repeats the cycle after biting another host.

Malaria can also be transmitted via blood transfusion, shared use of needles or syringes that are contaminated with blood, or organ transplant since malaria is in red blood cells of infected individuals.

The number of infected people observed in Cambodia each year exceeds more than a million out of which about 10-15% die (5). Victims of malaria are mostly children, infants, and pregnant women because of their weaker immune system (3). Forest inhabitants, border workers and migrants are also in high risk in getting the disease because of their increased exposure to mosquito vectors.

Studies have shown that global warming and climate changes may also lead to a rise in the incidence of malaria(4). Increasing temperatures, humidity, deforestation,and rains are all factors that may favor to mosquito spread to the areas where previously they did not exist which, in turn will lead to an increased incidence of malaria.

Description of the Plasmodium falciparum

A photomicrograph of a blood smear that contains plasmodium falciparum. (25)

Plasmodium falciparum is a species of the genus Plasmodium, which is of the Eukaryote domain and Plasmodiidae family. Plasmodium are much more complex than simple bacteria because of a “genetic complexity five times greater” (1). Their complex genome allows them more flexibility in various environments where simple bacteria can’t survive. Aside from having a complex genome, Plasmodium possesses various invasive stages for targeting specific host. Plasmodium falciparum are are the most dangerous and prominent due to being the cause of the majority of malaria cases and the cause of most severe malaria conditions.

Infection

A schematic of a Plasimodium falciparum mereozoite. (22)
Life Cycle of a Malaria parasite. (13)

Plasmodium possesses various forms, the most prominent being sporozoite, merozoite, and ookinete. These various forms of a plasmodium are directly tied to the cycle of infection. Sporozoite enters the human body via the saliva of mosquitoes during a blood meal. Sporozoites infect the hepatocytes (liver cell) within 30 minutes. From the hepatocyte, the parasite reproduces asexually into merozoites until they are released from the liver and enter the bloodstream. Merozoites then invade the erythrocytes (red blood cells) within 10 minutes. The merozoites continue proliferation in infected erythrocytes and also infect other uninfected erythrozytes. In an erythrocyte, merozoite can also differentiate to become gametocyte where they can be carried off by female mosquitoes after a blood meal. The gametocytes travel to the mosquitoes’ guts where they differentiate into male and female cells for fertilization. A zygote or ookinete is ultimately formed. The ookinete develops into sporozoites and venture into the saliva of the mosquitoes where they can further infect other human (7).

This cycle ties human and mosquitoes directly in the transmission and infection of malaria. In this relation, anopheline mosquitoes act as a vector and aid in spreading the infection. However, not all mosquitoes can be vectors. Only 68 out of 460 Anopheles can be vectors. Moreover, only female mosquitoes can take up gametocytes and transmit sporozoites as they are the only mosquitoes that bite.

Reasons for Symptoms

Many symptoms of malaria may be caused by the effects of merozoites interfering with the red blood cells' ability to carry oxygen. In infected erythrocytes, the cells are found to be deformed and stiffen due to merozoites making cellular structure and membrane changes. These changes are made to aid in the transport of parasitic nutrients and to satisfy parasitic needs. Hemoglobins also function as nutrients for the merozoites. Infected red blood cells are also more prone to cytoadhenerece known as auto-agglutination, rosetting, and sequestration. Rosetting is the adherence of infected red blood cells to uninfected red blood cells. Rosetting may be one of the mechanism for infection of other eyrthocytes by infected eyrthocytes. Auto-agglutination is adherence to other infected erythrocytes. Sequestration is the adherence of infected blood cells to the endothelial layer. The site of sequestration also prompts more infected cells to attach resulting in a buildup of infected cells. Sequestration hinders oxygen delivery to organs or tissue and may result coma symptom in cases of severe malaria. The combined effect of rosetting, sequestration, auto-agglutination, and consumption of hemoglobin by merozoites play a strong role in the hindrance of oxygen delivery. This may be the cause of flu-like symptoms of malaria. Other causes of symptoms are due to the release of malaria toxins. Malaria toxins can both damage tissue and over-stimulate cytokines. Cytokine is generally used to fight against microorganisms but overproduction result in inflammatory response and is more harmful than helpful. This may be the cause of fever in malaria.(8)

Prevention: Mosquito Bite

A female Anopheles mosquito takes a bite from its prey. (23)

Prevention can begin before the mosquito even bites. Mosquito net may also be used at night and while sleeping to avoid bites in sleep. Keeping windows closed and having insect repellent incense can help in the prevention of mosquito bites. Wearing long sleeves, pants, hats, and shoes rather than exposing skin with sandals, shorts and short sleeves can help in deterring and preventing mosquito bites. In countries of extreme humidity and temperature, these steps of prevention especially for clothings may not be very prudent. Insect repellent can be used along with minimizing exposed area of skin. For exposed areas of skin, applying insect repellents containing DEET will help. This is especially important in areas where travelers may encounter potentially lethal mosquito-vector diseases such as malaria. DEET effectiveness over a period of time is dependent on the concentration; higher concentrations means longer repellent protection. 100% DEET for 9.5 hours, 30% for 6.5 hours, 15% for 5 hours, and 10% for 3 hours. Although, it looks like using a higher amount of DEET would always be the best case, high concentrations of DEET carry greater toxicity without much benefit. Neurological toxicity may occur in humans as a result of high amounts of DEET exposure. The effectiveness of the repellent is also affected by temperatures, humidity, sweating, and exposure to water, so caution and awareness are key to preventing bug bites.

Permethrin is another insecticide that can protect against mosquito bites. This compound can be applied to clothing, shoes, tents, and bed nets, with research showing that they were more effective against mosquito bites than untreated articles. Contrary to claims, repellent-impregnated wristbands are ineffective against mosquito bites(11).

Anti-malaria drugs can also be combined with bite prevention to lower the risk of infection. This is known as chemoprophylaxis. The goal of this method is to prevent progression of the disease in the chance of transmittance of sporozoites from mosquito bites. However, chemoprophylaxis should only be limited to travelers staying short time due to cost of continuous anti-malaria drug usage. Usage of Chloroquine and pyrimethamine with sulfadoxine is advised against due to plasmodium falciparum increasing resistance to these drugs. Alternatives such as mefloquine, doxycycline, and atovaquone with proguanil should be used instead to minimize risk.(7)

Treatment

Increasing resistance of Plasmodium falciparum makes treatments, especially in Cambodia and other Southeast Asian countries, difficult. Drugs such as Chloroquine and Artemisinin based are inadvisable due to increasing resistance of the parasite worldwide. Artemisinin based drug such as Artesunate, prior to resistance, was the more recommended treatment due to fewer side effects and overall effectiveness. Outside of the high resistance area, Artemisinin-based treatment may still be used for treating P. falciparum cases of malaria. Chloroquine is still used for non-P. falciparum malaria but resistance often occurs and Chloroquine is often accompanied by Quinine. Treatments for falciparum malaria now would be in some form of Quinine for condition of mild and severe malaria in location of high resistance. However, Quinine has many side effects and in severe cases of malaria would require much stronger dosage or concentration. Quinine is also not suitable for children and pregnant women though it can still be administered with appropriate dosage. The side effects of Quinine in quinine sulfate used for treating mild malaria symptoms are ringing in ears, deafness, nausea, vomiting, etc. In severe cases, Quinine dihydrochloride is used and has a greater side effect. Quinine dihydrochloride can cause hypoglycemia and cardiac arrhythmias, especially in elderly patients and patients with heart disease. (27,28)

A potential new vaccine in development may be a permanent solution to malaria cased by falciparum. This new vaccine is Merozoite Surface Protein-3, or MSP3. MSP3 stimulates IgG, which is an antigen of monocyte and is crucial in the recognition and killing of plasmodium falciparum parasite. It is currently in clinical trial and has shown to be safe and satisfying in preventing malaria when tested in children of age 12 – 24 months.(29)

Why is this disease a problem in Cambodia?

Cambodia is one of a few countries in Southeast Asia that has been struck by the malaria epidemic. It is home to the world’s most drug-resistant strain of malaria and there are fears that more resistance to antimalarial drugs are developing. Plasmodium falciparum, one of the most common and, arguably, deadliest strands of malaria has been a major problem in Cambodia due to numerous factors.

Geography

Cambodia has an area of 69,898 square miles and about 60% this is comprised of forests and plains (5). This geography coupled with Monsoon-dominated weather makes Cambodia’s climate very moist. With its shady and wooded landscape, it makes Cambodia the perfect home for mosquitoes to survive and breed. Most of the population in Cambodia lives in these dense and moist forests where mosquitoes can transmit malaria to humans. Forest regions bordering Thailand and rubber plantations found in the East and Northwest are where malaria is likely to be found. About 15% of Cambodians are at elevated risks of malaria infection; of these forest inhabitants, migrant and border workers, pregnant women, infants, and children are the most susceptible to the disease (5).

Two packs of artesunate, an antimalarial drug, one authentic (right), one counterfeit (left). (5)

The Overwhelmed and Inadequate Health Care System

Poor health infrastructure and poor communication systems are also major contributing factors to the malaria epidemic in Cambodia. In high transmission areas such as forests, health facilities like hospitals are lacking, and transportation systems are insufficient or nonexistent. Poor road conditions, lack of suitable vehicles and a lack of telephone facilities lead to treatment delays for the infected in remote areas. Many of the affected areas are often inaccessible (18).

The inadequate health care system adds to the problem of malaria in Cambodia. There are often shortages of diagnostic kits and appropriate drugs, as well as a lack of qualified private practitioners. Many unqualified doctors and pharmacies do not follow the national treatment guidelines. There are also large numbers of fake drugs available in the market due to lack of strict regulation and quality control practices. The counterfeits may contain no active ingredients or contain ingredients different from the package label. In 1999, fake antimalarial drugs were responsible for at least 30 deaths in Cambodia (19).

Malaria's Economic Toll

Furthermore, the malaria epidemic greatly hinders Cambodia ability for economic improvements because it disables the work force, lowers educational achievements, slowed tourism and business investments. Due to the low economic growth, it causes a continued cycle of Cambodia’s inability to improve its living standards and therefore restricting its resources to prevent further outspread of malaria (16).

What is being done to address this problem

Government Policies

A blood smear that is used oh a rapid diagnostic test (RDT). (24)

In the year 2000, Cambodia was the first country to switch its anti-malarial drug policy to an artesunate combination therapy (ACT), in which they recommended a first-line treatment consisting of a combination of artesunate and mefloquine (A+M). ACT is important because artemisinin monotherapy (using artemisinin alone) will very likely cause a widespread artemisinin-resistant Plasmodium falciparum, which would be devastating. Other drugs, like chloroquine and pyrimethamine-sulfadoxine, usually used to treat malaria, can no longer be used because Plasmodium falciparum is multi-drug resistant and render them ineffective as treatment. However, recently, Artemisnin-resistant P. Falciparum has been emerging in parts of Western Cambodia, and since Artemisnin is the first line treatment, this is becoming a large problem. (9)

Included with this policy were: blister packaging of the A+M and separating them into three distinct age groups, marketing of the A+M product as "Malarine®" at a subsidized cost, public campaigning to educate the general public on fake anti-malarials and their negative effects, and advocating the usage of rapid diagnostic tests (RDT), also known as the dipstick test, which works by testing the patients blood smear for the presence of parasites transmitted by malaria, most prominently P. falciparum (14).

Insecticide Treated Mosquito Nets (ITN)

The government has also been distributing insecticide treated mosquito nets (ITN) which are useful preventative measures by creating a physical barrier between the parasite carrying mosquitoes and the potential victim, and is especially helpful, seeing as mosquitoes have a tendency to attack at night. These nets help by repelling, disabling, and/ or killing the mosquitoes that come in contact with the net (10). In 2007, 557,000 mosquito nets were distributed, and one million nets are going to be distributed in 2008. However, only 54.2% of Cambodians have received the mosquito nets; more volunteers are needed to distribute them (13).

Village Malaria Workers (VMW) and Malaria Outreach Teams (MOT)

A fairly efficient method currently used to ensure that the individuals who need the drug treatments receive and correctly use them are Village Malaria Workers (VMW) and Malaria Outreach Teams (MOT). The VMW are funded and run by “National Malaria Control Programme” and receive additional funding from the “Global Fund for AIDS, Tuberculosis and Malaria”, and the MOT is funded by "Médecins Sans Frontières" (MSF) (15). These groups greatly increase treatment accessibility by diffusing into areas including rural and difficult to reach endemic areas. They perform an effective survey of the local population with RDTs which are relatively inexpensive, mobile, and quick in relation to past tests done in laboratories. They provide high grade A+M (artemisinin-mefloquine drugs) virtually free to those infected and check on their progress and whether they have completed the full course of anti-malarials(14). And those who believe they have become infected then have convenient access to diagnosis and treatment.

What else could be done to address this problem

VMW and MOT Funding

Since the VMW and MOT are widely distributed and run in difficult-to-reach, endemic areas, there are large monetary costs associated with the start up and upkeep of the groups. More investment and the increase in the amount of willing and dedicated volunteers are needed to extenuate the reach of these groups, along with increased global awareness. With these, the positive effects of these groups can be even greater and more widespread.

Further Publicity Campaigning and Malaria Education

A Cambodian instructor educating her students on the perils of malaria. (31)

A method necessary for prevention includes an awareness campaign in which communities are educated on: 1) identifying symptoms of malaria and where to go and what to expect during treatment as well as 2) how to identify genuine and counterfeit blister packaging of A+M. They must also be 3) provided with insecticide treated nets (ITN), to reduce mosquito contact, at no or very low costs to encourage their use among the large numbers of people who live in poverty. The VMW and MOT can then go around and check to see whether people are utilizing the nets. Campaigning and ITNs will be costly and increased global awareness along with additional funding are imperative for the publicity campaign’s success.

Research for an Effective Artemisinin Substitute

Currently ACTs are more effective as treatment than other treatments because they decrease malaria transmission by preventing the development of P. falciparum gametocytes while at the same time, using a combination of drugs with distinct targets, this significantly decreases the chance of a mutation with resistance, because resistance to both drugs would be necessary (16). But at the same time, more research must be allotted towards finding other suitable drugs for treatment in the event that there is a widespread artemisinin resistance, which is now becoming a large possibility.

Parasites are rapidly becoming resistant to those drugs. For example, patients could have been clear of parasites in 2 days, however, now it takes about 3.5 days to kill (9). The World Health Organization (WHO) suggests several ways to reduce the artemisinin resistance: to detect all malaria cases in target areas and to kill all artemisinin-tolerant parasites, and limit the emergence of a widespread resistance by reducing exposure of the parasites to artemisinin. (26)

Research for a Vaccine

Currently, efforts to find a vaccine for P. falciparum have been relatively fruitless because it lives within the host's cells living largely undetected by the host immune system. Then these infected erythrocytes carrying the parasites come in contact with the dendritic cells and render them incapable of maturation thus not being able to carry out the protection mechanism through liver-stage immunity. Creating a vaccine with complete protection may be unlikely, but a vaccine that can reduce the intensity of the disease for younger children maybe possible.

Prohibiting the Sales and Distribution of Artemisinin Mono-therapies and Sub-standard Drugs

Contributing to this problem is the tendency for individuals living in rural endemic areas to seek treatment from informal health providers who would often times sell them artemisinin monotherapies, sub-standard artemisinin-mefloquine (A+M), or even fake drugs. Along with these low-grade drugs, individuals were not checked to see if they had finished the full course of the drug treatment (16). In many other instances, individuals were even given anti-malarials with the sign of a mere fever without any biological confirmation of malaria itself (16). These are large contributing factors to the drug resistances that Plasmodium falciparum has developed towards other previously effective anti-malarials. Blister packages are now used to ensure the user of high-grade A+M because it would be evident if the drug and packaging were tampered with and can ensure the user that the drug is not sub-standard nor fake. This system packages drugs recognized internationally by “Good Manufacturing Practice” (GMP) and are run by the “National Malaria Centre” (CNM) and supported by the “World Health Organization” (WHO) (15). Additionally, a government policy banning the use of artemisnin mono-treatments and the unnecessary prescription of anti-malarials without biological confirmation of the disease needs to be enacted, in order to reduce the risk of widespread artemisinin-resistant P. Falciparum. Artemisinin mono-treatments greatly increase the risk of creating an artemisinin-resistant P. Falciparum. So exposure to the drug should be limited, by only giving the drug to those who need it, and always giving artemisinin in combination with another drug.

Counterfeit Detecting and Decreasing Counterfeit Distribution

But these blister packages have been victim to counterfeiting, causing a new array of problems. Unfortunately, counterfeit blister packaging containing less than sufficient amounts of artemisinin are often being sold by informal health providers. This is a problem because the drug is not capable of wiping out P. falciparum, thus enabling the possibility of an artemisinin-resistant P. falciparum mutant, which would, again, be catastrophic (14). Genuine A+M blister packaging contains a specific hologram and other key features that consumers should learn to identify, which needs to be taught because the differences between counterfeit and authentic blister packaging are very subtle. But fake blister packages may contain holograms as well, and special attention to details is necessary to identify a counterfeit. As counterfeit awareness has been increasing, sometimes, the counterfeits now being produced are so well duplicated that the average consumers may not even be able to differentiate between the real and the fakes. Chemical testing, i.e. LC-MS and Raman spectroscopy, may even be necessary in order to determine its authenticity (17). Luckily, receiving free genuine A+M from VMW's and MOT's can assist in alleviating widespread distribution of counterfeits.

Summary

Malaria is a life-threatening disease which is caused by parasites that are transmitted to people via the bites of infected mosquitoes. It has spread almost everywhere, and more specifically at the low-income countries. Even though it is wide spread and fatal, it can be prevented and cured through various anti-malarial drugs available. Patients infected with malaria should get early treatment in order to prevent complications and decrease the number of deaths each year. Cambodia's climate allows for mosquitoes to thrive because a large portion of it is comprised of humid highlands and flooded fields since moist climates facilitate mosquito survival and breeding. The government of Cambodia made A+M the recommended first-line treatment, created campaigns to educate its people about the dangers of fake medication, and distributed Insecticide Treated Mosquito Nets (ITN); this has been effective in reducing the number of malarial infections and deaths caused by malaria. Other efforts of volunteers, such as Village Malaria Workers (VMW) and Malaria Outreach Teams (MOT) also help to prevent and stop the spread of malaria by providing authentic drug treatments to only those who need it and also creating a more accurate survey of malaria cases, even to those living in endemic, difficult to reach regions. However, there is a growing concern that P. falciparum is becoming resistant to anti-malarial drugs. And minimizing the exposure of parasites is necessary, through allotting only artemisinin combination therapy treatments to only those who need it, in order to limit the resistance. More funding for VMW and MOT, research geared towards finding potent substitutes for artemisinin and potential effective vaccines, and publicity campaigning education for the general public on how to recognize the symptoms of malaria and the distinctions between genuine and counterfeit A+M blister packages are needed to control and potentially completely eradicate P. falciparum in Cambodia.

References

1. NYU Langone Medical Center / New York University School of Medicine. “Genome of Parasite that Causes Relapsing Malaria Decoded.” 2009. ScienceDaily. Web. 9 Oct. 2008.

2. Pierce, Susan K., Miller, Louis H. “World Malaria Day 2009: What Malaria Knows about the Immune System that Immunologists Still Do Not. 2009.” The Journal of Immunology. 5 March 2009.

3. Wellcome Trust. “Drug-Resistant Malaria Has Emerged in Cambodia.” Science Daily. 4 Aug. 2009. Web. 13 Aug. 2009.

4. “Is Global Warming Likely to Cause an Increase Incidence of Malaria?” 2009. Libyan Journal of Medicine. 13 Feb. 2009. Web. 13 Aug. 2009

5. "Fewer Malaria Cases in Cambodia.” 2009. Population Reference Bureau. Dec. 2002. Web. 13 Aug. 2009

6. "World Malaria Report 2008: Epidemiological Profile of Cambodia." "World Malaria Report 2008". Geneva : World Health Organization. 2008. p.51-54.

7. Marcel Hommel, MD, PhD. "Malaria learning resource." Impact Malaria. October 01 2008. Web. 21 Aug. 2009

8. Chen, Qijun, Martha Schlichtherle, and Mats Wahlgren. "Molecular Aspects of Severe Malaria." Clinical microbiology reviews 13.3 (2000): 439-50. Print.

9. "Drug-resistant malaria has emerged in Cambodia." University of Oxford. 31 July 2009. Web. 31 July 2009.

10. “Insecticide-treated Mosquito Nets: a WHO Position Statement”. World Health Organization. 2008. Web. 21 Aug. 2009.

11. “Bites from mosquitoes, ticks, and other insects”. Mdtravelhealth. Web. 23 Aug. 2009.

12. Traveler’s Health, Centers for Disease Control and Prevention. Web. 21 Aug. 2009.

13. “Malaria”. National Institute of Allergy and Infectious Diseases. Web. 23 Aug. 2009.

14. Yeung, Shunmay, Wim Van Damme, Doung Socheat, Nicholas J. White, and Anne Mills. "Access to artemisinin combination therapy for malaria in remote areas of Cambodia." Malaria Journal 96th ser. 7.1 (2008). Malaria Journal. Web. 26 Aug. 2009.

15. Yeung, Shunmay, Wim Van Damme, Doung Socheat, Nicholas J. White, and Anne Mills. "Cost of increasing access to artemisinin combination therapy: the Cambodian experience." Malaria Journal 84th ser. 7.1 (2008). BioMed Central Ltd. Web. 26 Aug. 2009.

16. Guerin, Philippe J., Piero Olliaro, Francois Nosten, Pierre Druilhe, Ramanan Laxminarayan, Fred Binka, Wen L. Kilama, Nathan Ford, and Nicholas J. White. "Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development." The Lancet Infections Diseases 2.9 (2002): 564-73. The Lancet. Web. 26 Aug. 2009.

17. Krystyn, Paul N. Newton, Micheal D. Green, Marleen De Veij, Peter Vandenabeele, David Pizzanelli, Mayfong Mayxay, Arjen Dondorp, and Facundo M. Fernandez. "Characterization of Counterfeit Artesunate Antimalarial Tablets from South East Asia." The American Journal of Tropical Medicin and Hygiene 75.5 (2006): 804-11. The American Journal of Tropical Medicine and Hygiene. Web. 26 Aug. 2009.

18. “Malaria Situation in Cambodia, in 2003.” National Malaria Center for Parasitology, Entomology & Malaria Control. Web. 20 August 2009.

19. “Counterfeit and Substandard Antimalarial Drugs.” Centers for Disease Control and Prevention. 26 July 2006. Web. 24 Aug. 2009.

20. "Scientists Find Malaria Jumping from Chimps to Humans.” AFP. 3 Aug. 2009. Web. 21 Aug. 2009.

21. Jacobs, Margo. Breaking the Cycle of Malaria and Poverty. 2009. New World Outlook. July/Aug. 2009. Web. 21 Aug. 2009.

22. Long, Carole A. "Carole A. Long, Ph.D., Malaria Immunology Section, Laboratory of Malaria and Vector Research, NIAID, NIH." National Institute of Allergy and Infectious Diseases. Web. 28 Aug. 2009.

23. “Mosquitoes” Centers of Disease Control and Prevention. Web. 21 Aug. 2009.

24. “Malaria self-test module”. Royal Perth Hospital. Web. 21 Aug. 2009.

25. Public Health Image Library, Centers of Disease Control and Prevention. Web. 21 Aug. 2009.

26. Chinnock , Paul . "Containing artemisinin resistance ". TropIKA. 2 Mar 2009. Web. 24 Aug. 2009.

27. Roe, J. K., and G. Pasvol. "New Developments in the Management of Malaria in Adults." QJM (2009)Print.

28. Dondorp, Arjen M., et al. "Artemisinin Resistance in Plasmodium Falciparum Malaria." The New England journal of medicine 361.5 (2009): 455-67. Print.

29. Lusingu, John, et al. "Satisfactory Safety and Immunogenicity of MSP3 Malaria Vaccine Candidate in Tanzanian Children Aged 12-24 Months." Malaria Journal 8.1 (2009): 163. Print.

30. "Häggström diagrams". Wikipedia Commons. Web. 21 Aug. 2009.

31. "Education". USAID Cambodia. Web. 21 Aug. 2009.

Edited by Betsy Chiem, Lusine Minasyan, Chuong Do, Katherine Leu, Albert Luong and Ben Cho, students of Rachel Larsen